In about 80% of metastatic prostate cancer patients, primary androgen ablation leads to symptomatic improvement and a decrease in serum prostate-specific antigen (PSA), but in all patients the disease will eventually become refractory to hormone treatment [2]. This evidence concerns the gene KLK3 and metastatic prostate carcinoma.